Literature DB >> 24899538

Baroreflex activation: from mechanisms to therapy for cardiovascular disease.

Radu Iliescu1, Ionut Tudorancea, Thomas E Lohmeier.   

Abstract

Recent technical advances have led to the development of a medical device that can reliably activate the carotid baroreflex with an acceptable degree of safety. Because activation of the sympathetic nervous system plays an important role in the pathogenesis of hypertension and heart failure, the unique ability of this device to chronically suppress central sympathetic outflow in a controlled manner suggests potential value in the treatment of these conditions. This notion is supported by both clinical and experimental animal studies, and the major aim of this article is to elucidate the physiological mechanisms that account for the favorable effects of baroreflex activation therapy in patients with resistant hypertension and heart failure. Illumination of the neurohormonal, renal, and cardiac actions of baroreflex activation is likely to provide the means for better identification of those patients that are most likely to respond favorably to this device-based therapy.

Entities:  

Mesh:

Year:  2014        PMID: 24899538      PMCID: PMC4364442          DOI: 10.1007/s11906-014-0453-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Authors:  George L Bakris; Mitra K Nadim; Hermann Haller; Eric G Lovett; Jill E Schafer; John D Bisognano
Journal:  J Am Soc Hypertens       Date:  2012-02-15

2.  Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.

Authors:  Uta C Hoppe; Mathias-Christoph Brandt; Rolf Wachter; Joachim Beige; Lars Christian Rump; Abraham A Kroon; Adam W Cates; Eric G Lovett; Hermann Haller
Journal:  J Am Soc Hypertens       Date:  2012-06-12

3.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

Authors:  John D Bisognano; George Bakris; Mitra K Nadim; Luis Sanchez; Abraham A Kroon; Jill Schafer; Peter W de Leeuw; Domenic A Sica
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

Review 4.  Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation.

Authors:  Thomas E Lohmeier; Radu Iliescu
Journal:  J Appl Physiol (1985)       Date:  2012-07-12

Review 5.  Vagus nerve stimulation in experimental heart failure.

Authors:  Hani N Sabbah; Itamar Ilsar; Asaph Zaretsky; Sharad Rastogi; Mengjun Wang; Ramesh C Gupta
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

6.  Systemic and renal-specific sympathoinhibition in obesity hypertension.

Authors:  Thomas E Lohmeier; Radu Iliescu; Boshen Liu; Jeffrey R Henegar; Christine Maric-Bilkan; Eric D Irwin
Journal:  Hypertension       Date:  2011-12-19       Impact factor: 10.190

Review 7.  Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy.

Authors:  Thomas E Lohmeier; Radu Iliescu
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

8.  Renal responses to chronic suppression of central sympathetic outflow.

Authors:  Radu Iliescu; Eric D Irwin; Dimitrios Georgakopoulos; Thomas E Lohmeier
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

9.  Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension.

Authors:  Teba Alnima; Peter W de Leeuw; Frans E S Tan; Abraham A Kroon
Journal:  Hypertension       Date:  2013-04-15       Impact factor: 10.190

10.  Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension.

Authors:  Radu Iliescu; Ionut Tudorancea; Eric D Irwin; Thomas E Lohmeier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-02       Impact factor: 4.733

View more
  8 in total

1.  Chronic Interactions Between Carotid Baroreceptors and Chemoreceptors in Obesity Hypertension.

Authors:  Thomas E Lohmeier; Radu Iliescu; Ionut Tudorancea; Radu Cazan; Adam W Cates; Dimitrios Georgakopoulos; Eric D Irwin
Journal:  Hypertension       Date:  2016-05-09       Impact factor: 10.190

2.  Effects of low-level carotid baroreflex stimulation on atrial electrophysiology.

Authors:  Mingyan Dai; Mingwei Bao; Jiafen Liao; Lilei Yu; Yanhong Tang; He Huang; Xi Wang; Congxin Huang
Journal:  J Interv Card Electrophysiol       Date:  2015-04-15       Impact factor: 1.900

Review 3.  Electrical carotid sinus stimulation: chances and challenges in the management of treatment resistant arterial hypertension.

Authors:  Kristine Chobanyan-Jürgens; Jens Jordan
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 4.  The baroreflex as a long-term controller of arterial pressure.

Authors:  Thomas E Lohmeier; Radu Iliescu
Journal:  Physiology (Bethesda)       Date:  2015-03

5.  Baroreflex gain and vasomotor sympathetic modulation in resistant hypertension.

Authors:  Isabelle Magalhães Guedes Freitas; Leonardo Barbosa de Almeida; Natália Portela Pereira; Pedro Augusto de Carvalho Mira; Rogério Baumgratz de Paula; Daniel Godoy Martinez; Edgar Toschi-Dias; Mateus Camaroti Laterza
Journal:  Clin Auton Res       Date:  2017-04-06       Impact factor: 4.435

6.  The ability of baroreflex activation to improve blood pressure and resistance vessel function in spontaneously hypertensive rats is dependent on stimulation parameters.

Authors:  Gean Domingos-Souza; Fernanda Machado Santos-Almeida; Cesar Arruda Meschiari; Nathanne S Ferreira; Camila A Pereira; Nayara Pestana-Oliveira; Thaís Caroline Prates-Costa; Rita C Tostes; Carl White; Rubens Fazan
Journal:  Hypertens Res       Date:  2021-03-12       Impact factor: 3.872

Review 7.  Angiotensin II-superoxide-NFκB signaling and aortic baroreceptor dysfunction in chronic heart failure.

Authors:  Dongze Zhang; Robert L Muelleman; Yu-Long Li
Journal:  Front Neurosci       Date:  2015-10-16       Impact factor: 4.677

8.  Reduced Renal Mass, Salt-Sensitive Hypertension Is Resistant to Renal Denervation.

Authors:  Ionut Tudorancea; Thomas E Lohmeier; Barbara T Alexander; Dragos Pieptu; Dragomir N Serban; Radu Iliescu
Journal:  Front Physiol       Date:  2018-04-30       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.